<DOC>
	<DOCNO>NCT00151762</DOCNO>
	<brief_summary>This extension study design evaluate long-term safety tolerability colesevelam hydrochloride ( WelChol® ) patient type 2 diabetes .</brief_summary>
	<brief_title>Long-Term Study Safety Efficacy WelChol® Additional Therapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Inclusion/Rollover Criteria : Patients complete study WEL301 , WEL302 , WEL303 treatment compliance least 80 % Patients complete study WEL301 , WEL302 , WEL303 meet withdrawal criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Open label , Diabetes Mellitus</keyword>
	<keyword>Long term safety study , extension study</keyword>
</DOC>